COST-EFFECTIVENESS OF TOFACITINIB FOR PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN CHINA

被引：0
|
作者：
Tian, L. [1 ]
Guo, Q. [2 ]
Xiong, X. [1 ]
Wang, L. [1 ]
Chen, Y. [3 ]
Dong, P. [3 ]
Ma, A. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Jiangsu, Peoples R China
[2] Renji Hosp, Shanghai, Peoples R China
[3] Pfizer Investment Co Ltd, Beijing, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.1128
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMS18
引用
收藏
页码：S241 / S241
页数：1
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF BIOLOGICAL TREATMENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN TAIWAN
    Chen, H. F.
    Lin, H. Y.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A673 - A673
  • [42] Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis
    Peng, Kuan
    Chan, Shirley C. W.
    Wang, Yang
    Cheng, Franco W. T.
    Yeung, Winnie W. Y.
    Jiao, Yuanshi
    Chan, Esther W. Y.
    Wong, Ian C. K.
    Lau, Chak-Sing
    Li, Xue
    [J]. JAMA NETWORK OPEN, 2024, 7 (06)
  • [43] THE COST-EFFECTIVENESS OF BIOLOGIC DMARDS IN PATIENTS WITH SEVERE OR MILD-TO-SEVERE RHEUMATOID ARTHRITIS AFTER CONVENTIONAL DMARDS
    Wailoo, A. J.
    Stevenson, M.
    Tosh, J.
    Hernandez, M.
    Stevens, J. W.
    Archer, R.
    Simpson, E.
    Hock, Everson E.
    Scott, D.
    Young, A.
    Paisley, S.
    Williams, K.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A380 - A380
  • [44] COST EFFECTIVENESS ANALYSIS OF CERTOLIZUMAB IN COMBINATION WITH METHOTREXATE IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN SAUDI ARABIA
    Alghamdi, A.
    Alothaim, A.
    Almalaq, H.
    Balkhi, B.
    Alshehri, N.
    [J]. VALUE IN HEALTH, 2020, 23 : S596 - S596
  • [45] COST-EFFECTIVENESS SIMULATION MODEL OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS BASED ON DISEASE ACTIVITY IN GERMANY
    Beresniak, A.
    Baerwald, C.
    Zeidler, H.
    Gromnica-Ihle, E.
    Kruger, K.
    Neubauer, A. S.
    Dupont, D.
    Merkesdal, S.
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A440 - A440
  • [46] Cost-effectiveness of rituximab (Mabthera) compared with abatacept (Orencia) for the treatment of moderate/severe rheumatoid arthritis (RA) in the united kingdom
    Lewis, G.
    Kielhorn, A.
    Diamantopoulos, A.
    [J]. VALUE IN HEALTH, 2007, 10 (06) : A249 - A250
  • [47] ADAPTABILITY, EFFECTIVENESS AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS
    Rodriguez, Fernando
    Aza, Anggie
    Cabrera, Michael
    Santos-Moreno, Pedro
    Buitrago-Garcia, Diana
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 2154 - 2154
  • [48] Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Lopez-Del Val, Alejandro
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (06) : 355 - 360
  • [49] Cost-effectiveness of rituximab strategies in rheumatoid arthritis
    Seror, Raphaele
    Mariette, Xavier
    [J]. LANCET, 2017, 389 (10067): : 365 - 366
  • [50] Cost-effectiveness of infliximab for rheumatoid arthritis in Spain
    Wong, JB
    Ballina, J
    Fernandez-Sueiro, J
    Garcia-Vadillo, J
    Gonzalez-Fernandez, C
    Gonzalez-Crespo, M
    Gratacos, J
    Ivorra, J
    Navarro-Sarabia, F
    Tornero, J
    Casado, MA
    Fosbrook, L
    Pocovi, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 520 - 521
12345